Oskana Μιασ Δόσησ (Levocarnitine)

Oskana Μιασ Δόσησ provides levocarnitine supplementation for conditions involving impaired fatty‑acid transport and metabolism.

• Primary carnitine deficiency: restores intracellular carnitine levels to improve mitochondrial fatty‑acid oxidation.
• Secondary carnitine deficiency: replenishes depleted carnitine stores caused by renal loss or medication effects.
• Metabolic disorders affecting fatty‑acid oxidation: supports energy production in inherited enzyme deficiencies.
• Support of energy metabolism in patients with certain medical conditions: helps maintain normal muscle function and reduces fatigue.

• Levocarnitine acts as a carrier molecule that transports long‑chain fatty acids across the inner mitochondrial membrane. By forming acyl‑carnitine esters, it enables β‑oxidation of fatty acids, thereby facilitating ATP generation and supporting normal cellular energy metabolism, especially in tissues with high oxidative demand such as heart and skeletal muscle.

Levocarnitine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort
• Headache
• Metallic taste in the mouth

Serious or Rare Side Effects

• Allergic reactions such as rash, urticaria, or anaphylaxis
• Elevated serum creatinine indicating renal stress
• Hepatotoxicity manifested by abnormal liver enzymes
• Muscle weakness or myopathy
• Seizures (rare)
• Severe hypotension following rapid intravenous administration (if applicable)

Before initiating therapy, consider the following precautions.

• Assess baseline carnitine levels: confirm deficiency to justify supplementation.
• Monitor renal function: adjust dose in patients with impaired kidney function.
• Adjust for hepatic impairment: use lower doses if liver disease is present.
• Avoid in known hypersensitivity: discontinue if allergic signs appear.
• Use with caution when combined with valproic acid or other drugs that may alter carnitine metabolism.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levocarnitine may interact with several medications; awareness of these interactions helps maintain safety.

Major Interactions (Avoid)

• Valproic acid: may reduce levocarnitine effectiveness and increase toxicity risk.
• Certain antibiotics (e.g., ceftriaxone): can bind carnitine and lower its plasma concentration.
• Warfarin: potential alteration of INR values requiring close monitoring.

Moderate Interactions (Monitor Closely)

• Anticonvulsants such as carbamazepine: may increase carnitine clearance.
• Diuretics: can enhance urinary loss of carnitine, necessitating dose adjustment.
• Thyroid hormone therapy: may affect carnitine metabolism and require periodic assessment.